Anemia is a condition of insufficient hemoglobin in the blood or red blood cells or insufficient normal red blood cell count (erythrocyte count). Anemia can cause fatigue and shortness of breath. A complete blood count is used to assess the severity of anemia, and is often used as a guideline for treatment of anemia by blood transfusions.\n
Anemia is the most common form of anemia in the U.S. and affects nearly 5% of the U.S. population, predominantly women, and disproportionately of different ethnic groups. The prevalence of anemia is highest in the elderly, women, and minorities. It can be improved with education, increased screening, and improved treatments.
Patients who achieve sufficient hemoglobin levels by adopting one of the recommended levels of daily iron or folic acid supplements may be able to achieve normal hemoglobin levels without regular medical therapy.
Iron deficiency is very common among Australian women. A high intake of iron may be protective against unexplained iron deficiency. A lower iron status does have a significant effect on aerobic exercise performance. Poor intake of iron from food contributes to low iron status in Australian women.
There are two major categories of treatment in primary and secondary care settings for anemia: (1) treating the cause of the anemia before it is diagnosed; and (2) treating it with medications. There are no treatments which are known to be effective when used as part of treatment for the anemia as a condition in itself. However, there are several drugs the majority of which are approved for other indications that would be effective for use in anemia associated with CKD.
Signs can be detected and assessed qualitatively using medical knowledge to elicit an 'a-ha!' response from the person to reveal the severity of their symptoms.
Anemia may have several causes. While some of the causes can be corrected such as blood loss, iron deficiency can't be treated with the iron supplement, iron deficiency can be treated with blood transfusion.
Regn7257 was safe and well tolerated in this pre-specified, prospective, exploratory study, despite the expected occurrence of anemia. The data from two short-term studies support a longer use of Regn7257 beyond the expected follow-up period.
The first published regn7257 data demonstrate its effectiveness in treatment of neutropenia following myeloablative chemotherapy. Clinical data from a phase II clinical trial of regn7257 in solid tumors were reported. In conjunction with the data on regn7257 published to date, the investigational new drug (IND) application for the use of regn7257 in the treatment of neutropenia following myeloablative neutropenic chemotherapy in oncology patients is currently pending.
The overall clinical benefit associated with regn 7257 has been disappointing, which may potentially be attributed to its typically used in combination with chemotherapy or biologic therapy. Further study by combining regn 7257 with other new agents and the use of a matched control for the chemotherapy regimen is recommended.
Regn 7257 shows promise as a potent and well-tolerated immunotherapeutic in patients with chronic lymphocytic leukemia. At an early stage of this Phase II trial and in light of the excellent safety profile achieved as well as the remarkable clinical benefit, this compound will be considered for larger clinical trials.